St. John's Institute of Dermatology 13 09 07 NB From: Sent: 13 September 2007 17:11 To: Natalie Bemrose Cc: Subject: Infliximab for the treatment of adults with psoriasis (STA)
Follow Up Flag: Follow up Flag Status: Completed
Dear Natalie I have reviewed the evaluation report on the above consultation and have had sight of the British Association of Dermatologists (BAD) respones to the questions raised. I would like to state that I fully concur with the points the BAD have made and have no further comments to make.
Best wishes, Karina Jackson
Karina Jackson Nurse Consultant St. John's Institute of Dermatology St. Thomas's Hospital London SE1 7EH
Tel. direct line:
The information contained in this message and or attachments is intended only for the person or entity to which it is addressed and may contain confidential and/or privileged material.
Unless otherwise specified, the opinions expressed herein do not necessarily represent those of Guy's and St Thomas' NHS Foundation Trust or any of its subsidiaries.
The information contained in this e-mail may be subject to public disclosure under the Freedom of Information Act 2000. Unless the information is legally exempt from disclosure, the confidentiality of this e-mail and any replies cannot be guaranteed.
Any review, retransmission, dissemination or other use of, or taking of any action in reliance upon, this information by persons or entities other than the intended recipient is prohibited. If you received this in error, please contact

the sender and delete the material from any system and destroy any copies.

We make every effort to keep our network free from viruses. However, it is your responsibility to ensure that this e-mail and any attachments are free of

We make every effort to keep our network free from viruses. However, it is your responsibility to ensure that this e-mail and any attachments are free of viruses as we can take no responsibility for any computer virus which might be transferred by way of this e-mail.

Delivered via MessageLabs